# Inseego Corp.: financial statements, quarterly

INSG · Nasdaq · CIK 1022652 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/insg.md) · [Financials](/companies/insg/financials.md) · [Filings](/companies/insg/filings.md) · [Insiders](/companies/insg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/insg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [41.4](/filings/0001022652-24-000016.md) | [35.9 d](/filings/0001022652-25-000005.md) | [37.5](/filings/0001022652-25-000012.md) | [51.6](/filings/0001022652-25-000017.md) | [54.0](/filings/0001022652-25-000024.md) | [48.1 d](/filings/0001022652-26-000005.md) | [31.7](/filings/0001022652-26-000010.md) | [40.2](/filings/0001022652-26-000013.md) | [45.9](/filings/0001022652-25-000024.md) | [48.4 d](/filings/0001022652-26-000005.md) | [34.3](/filings/0001022652-26-000010.md) | [44.0](/filings/0001022652-26-000013.md) |
| Cost of revenue | $m | [43.5](/filings/0001022652-24-000016.md) | not reported | [27.6](/filings/0001022652-24-000006.md) | [36.1](/filings/0001022652-24-000012.md) | [35.2](/filings/0001022652-24-000016.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [(2.2)](/filings/0001022652-24-000016.md) | [9.3 d](/filings/0001022652-25-000005.md) | [13.2](/filings/0001022652-25-000012.md) | [18.8](/filings/0001022652-25-000017.md) | [18.8](/filings/0001022652-25-000024.md) | [17.9 d](/filings/0001022652-26-000005.md) | [15.0](/filings/0001022652-26-000010.md) | [16.5](/filings/0001022652-26-000013.md) | [19.1](/filings/0001022652-25-000024.md) | [20.4 d](/filings/0001022652-26-000005.md) | [16.6](/filings/0001022652-26-000010.md) | [14.8](/filings/0001022652-26-000013.md) |
| Research and development | $m | [5.2](/filings/0001022652-24-000016.md) | [5.4 d](/filings/0001022652-25-000005.md) | [4.7](/filings/0001022652-25-000012.md) | [5.2](/filings/0001022652-25-000017.md) | [5.2](/filings/0001022652-25-000024.md) | [5.6 d](/filings/0001022652-26-000005.md) | [4.5](/filings/0001022652-26-000010.md) | [4.8](/filings/0001022652-26-000013.md) | [4.9](/filings/0001022652-25-000024.md) | [5.6 d](/filings/0001022652-26-000005.md) | [5.8](/filings/0001022652-26-000010.md) | [5.3](/filings/0001022652-26-000013.md) |
| Operating income | $m | [(19.1)](/filings/0001022652-24-000016.md) | [(7.8) d](/filings/0001022652-25-000005.md) | [(2.9)](/filings/0001022652-25-000012.md) | [1.9](/filings/0001022652-25-000017.md) | [1.0](/filings/0001022652-25-000024.md) | [1.8 d](/filings/0001022652-26-000005.md) | [(0.4)](/filings/0001022652-26-000010.md) | [1.3](/filings/0001022652-26-000013.md) | [2.2](/filings/0001022652-25-000024.md) | [1.3 d](/filings/0001022652-26-000005.md) | [(3.6)](/filings/0001022652-26-000010.md) | [(7.2)](/filings/0001022652-26-000013.md) |
| Income tax | $m | [0.0](/filings/0001022652-24-000016.md) | [(0.0) d](/filings/0001022652-25-000005.md) | [0.0](/filings/0001022652-25-000012.md) | [0.1](/filings/0001022652-25-000017.md) | [0.0](/filings/0001022652-25-000024.md) | [0.5 d](/filings/0001022652-26-000005.md) | [0.0](/filings/0001022652-26-000010.md) | [0.0](/filings/0001022652-26-000013.md) | [(0.0)](/filings/0001022652-25-000024.md) | [0.0 d](/filings/0001022652-26-000005.md) | [0.0](/filings/0001022652-26-000010.md) | [0.0](/filings/0001022652-26-000013.md) |
| Net income | $m | [(21.8)](/filings/0001022652-24-000016.md) | [(14.3) d](/filings/0001022652-25-000005.md) | [(4.5)](/filings/0001022652-25-000012.md) | [0.6](/filings/0001022652-25-000017.md) | [9.0](/filings/0001022652-25-000024.md) | [(0.6) d](/filings/0001022652-26-000005.md) | [(1.6)](/filings/0001022652-26-000010.md) | [0.5](/filings/0001022652-26-000013.md) | [1.4](/filings/0001022652-25-000024.md) | [0.5 d](/filings/0001022652-26-000005.md) | [(4.5)](/filings/0001022652-26-000010.md) | [(8.4)](/filings/0001022652-26-000013.md) |
| Diluted EPS | $ per share | [(1.93)](/filings/0001022652-24-000016.md) | not reported | [(0.44)](/filings/0001022652-25-000012.md) | [(0.02)](/filings/0001022652-25-000017.md) | [(0.06)](/filings/0001022652-25-000024.md) | not reported | [(0.16)](/filings/0001022652-26-000010.md) | [(0.03)](/filings/0001022652-26-000013.md) | [0.03](/filings/0001022652-25-000024.md) | not reported | [0.65](/filings/0001022652-26-000010.md) | [(0.52)](/filings/0001022652-26-000013.md) |
| Basic EPS | $ per share | [(1.93)](/filings/0001022652-24-000016.md) | not reported | [(0.44)](/filings/0001022652-25-000012.md) | [(0.02)](/filings/0001022652-25-000017.md) | [0.66](/filings/0001022652-25-000024.md) | not reported | [(0.16)](/filings/0001022652-26-000010.md) | [(0.03)](/filings/0001022652-26-000013.md) | [0.03](/filings/0001022652-25-000024.md) | not reported | [0.66](/filings/0001022652-26-000010.md) | [(0.52)](/filings/0001022652-26-000013.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [18.9](/filings/0001022652-23-000035.md) | [2.4](/filings/0001022652-25-000005.md) | [12.3](/filings/0001022652-24-000006.md) | [49.0](/filings/0001022652-24-000012.md) | [12.0](/filings/0001022652-24-000016.md) | [39.6](/filings/0001022652-26-000005.md) | [35.1](/filings/0001022652-25-000012.md) | [13.2](/filings/0001022652-25-000017.md) | [14.6](/filings/0001022652-25-000024.md) | [24.9](/filings/0001022652-26-000013.md) | [19.3](/filings/0001022652-26-000010.md) | [1.9](/filings/0001022652-26-000013.md) |
| Current assets | $m | [63.9](/filings/0001022652-23-000035.md) | [58.2](/filings/0001022652-25-000005.md) | [63.1](/filings/0001022652-24-000006.md) | [93.1](/filings/0001022652-24-000012.md) | [85.1](/filings/0001022652-24-000016.md) | [72.9](/filings/0001022652-26-000005.md) | [66.2](/filings/0001022652-25-000012.md) | [56.2](/filings/0001022652-25-000017.md) | [57.0](/filings/0001022652-25-000024.md) | [64.1](/filings/0001022652-26-000013.md) | [53.3](/filings/0001022652-26-000010.md) | [58.1](/filings/0001022652-26-000013.md) |
| Total assets | $m | [137](/filings/0001022652-23-000035.md) | [122](/filings/0001022652-25-000005.md) | [122](/filings/0001022652-24-000006.md) | [150](/filings/0001022652-24-000012.md) | [113](/filings/0001022652-24-000016.md) | [100.0](/filings/0001022652-26-000005.md) | [93.0](/filings/0001022652-25-000012.md) | [83.1](/filings/0001022652-25-000017.md) | [85.8](/filings/0001022652-25-000024.md) | [93.8](/filings/0001022652-26-000013.md) | [84.2](/filings/0001022652-26-000010.md) | [90.4](/filings/0001022652-26-000013.md) |
| Current liabilities | $m | [59.9](/filings/0001022652-23-000035.md) | [55.9](/filings/0001022652-25-000005.md) | [59.5](/filings/0001022652-24-000006.md) | [239](/filings/0001022652-24-000012.md) | [189](/filings/0001022652-24-000016.md) | [63.5](/filings/0001022652-26-000005.md) | [59.1](/filings/0001022652-25-000012.md) | [46.2](/filings/0001022652-25-000017.md) | [43.9](/filings/0001022652-25-000024.md) | [48.4](/filings/0001022652-26-000013.md) | [52.1](/filings/0001022652-26-000010.md) | [54.3](/filings/0001022652-26-000013.md) |
| Total liabilities | $m | [228](/filings/0001022652-23-000035.md) | [224](/filings/0001022652-25-000005.md) | [228](/filings/0001022652-24-000006.md) | [251](/filings/0001022652-24-000012.md) | [198](/filings/0001022652-24-000016.md) | [113](/filings/0001022652-26-000005.md) | [106](/filings/0001022652-25-000012.md) | [93.6](/filings/0001022652-25-000017.md) | [93.5](/filings/0001022652-25-000024.md) | [97.9](/filings/0001022652-26-000013.md) | [110](/filings/0001022652-26-000010.md) | [121](/filings/0001022652-26-000013.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | [0.0](/filings/0001022652-24-000016.md) | not reported | [13.7](/filings/0001022652-24-000012.md) | [6.0](/filings/0001022652-24-000016.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(90.8)](/filings/0001022652-23-000035.md) | [(102)](/filings/0001022652-26-000005.md) | [(106)](/filings/0001022652-25-000017.md) | [(102)](/filings/0001022652-25-000024.md) | [(85.1)](/filings/0001022652-25-000024.md) | [(12.9)](/filings/0001022652-26-000013.md) | [(13.0)](/filings/0001022652-26-000013.md) | [(10.5)](/filings/0001022652-26-000013.md) | [(7.7)](/filings/0001022652-25-000024.md) | [(4.0)](/filings/0001022652-26-000013.md) | [(25.4)](/filings/0001022652-26-000013.md) | [(30.6)](/filings/0001022652-26-000013.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [9.7 d](/filings/0001022652-24-000016.md) | [(16.4) d](/filings/0001022652-25-000005.md) | [5.2](/filings/0001022652-25-000012.md) | [27.6 d](/filings/0001022652-25-000017.md) | [14.8 d](/filings/0001022652-25-000024.md) | [(14.2) d](/filings/0001022652-26-000005.md) | [(3.5)](/filings/0001022652-26-000010.md) | [(4.5) d](/filings/0001022652-26-000013.md) | [3.2 d](/filings/0001022652-25-000024.md) | [12.0 d](/filings/0001022652-26-000005.md) | [1.7](/filings/0001022652-26-000010.md) | [(23.8) d](/filings/0001022652-26-000013.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001022652-24-000016.md) | [(0.2) d](/filings/0001022652-25-000005.md) | [0.0](/filings/0001022652-25-000012.md) | [0.0 d](/filings/0001022652-25-000017.md) | [0.0 d](/filings/0001022652-25-000024.md) | [0.1 d](/filings/0001022652-26-000005.md) | [0.0](/filings/0001022652-26-000010.md) | [0.2 d](/filings/0001022652-26-000013.md) | [0.1 d](/filings/0001022652-25-000024.md) | [0.3 d](/filings/0001022652-26-000005.md) | [0.1](/filings/0001022652-26-000010.md) | [0.3 d](/filings/0001022652-26-000013.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [108](/filings/0001022652-23-000035.md) | [10.9](/filings/0001022652-24-000006.md) | [11.1](/filings/0001022652-24-000012.md) | [11.7](/filings/0001022652-24-000016.md) | [11.9](/filings/0001022652-25-000012.md) | [11.9](/filings/0001022652-25-000017.md) | [13.2](/filings/0001022652-25-000024.md) | [15.0](/filings/0001022652-26-000010.md) | [15.0](/filings/0001022652-26-000013.md) | [15.5](/filings/0001022652-25-000024.md) | [16.4](/filings/0001022652-26-000010.md) | [16.3](/filings/0001022652-26-000013.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 16,420,592 at 2026-07-29, from the cover of the [10-Q filed 2026-08-06](/filings/0001022652-26-000013.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.